Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization

被引:9
|
作者
Mizugaki, Hidenori [1 ]
Yamamoto, Noboru [1 ]
Fujiwara, Yutaka [1 ]
Nokihara, Hiroshi [1 ]
Yamada, Yasuhide [1 ]
Tamura, Tomohide [1 ]
机构
[1] Natl Canc Ctr, Tokyo 1040045, Japan
关键词
TYROSINE KINASE INHIBITOR; EVERY; 3; WEEKS; SUBEROYLANILIDE HYDROXAMIC ACID; ADVANCED SOLID TUMORS; DOSE-ESCALATION; MONOCLONAL-ANTIBODY; IXABEPILONE BMS-247550; LIPOSOMAL DOXORUBICIN; INTRAVENOUS-INFUSION; CAMPTOTHECIN ANALOG;
D O I
10.1200/JCO.2014.58.4953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose In Japan, phase I trials, except first-in-human trials, are usually initiated from approximately 50% of the maximum-tolerated dose (MTD) or maximum administered dose (MAD) determined during the initial phase I trials in North America and Europe (the West). However, the key findings of phase I trials in Japan and the West, such as dose-limiting toxicity (DLT) profiles and MTD or MAD levels, have not been compared. Patients and Methods We retrospectively analyzed data for patients enrolled onto single-agent phase I trials at the National Cancer Center Hospital between 1995 and 2012. DLT profiles, MTDs, and MADs of single-agent phase I trials in Japan were compared with those from trials in the West that were obtained from the literature. Results A total of 777 patients were enrolled onto 54 single-agent phase I trials, including five first-in-human trials. DLTs were observed in 11.1% of the patients. Importantly, 66.4% of the DLTs were observed within a dose range (80% to 120%) similar to those reported for the trials in the West. The majority of MTDs or MADs could be considered similar between patients, and 80.3% of the drugs had similar MTDs or MADs in the West. Conclusion The toxicity profiles of single-agent phase I agents determined from trials conducted in Japan were comparable to those obtained from trials in the West. We believe that phase I trials in Japan could be conducted over timelines similar to those in the West, allowing for global or parallel phase I clinical trials. (C) 2015 by American Society of Clinical Oncology
引用
收藏
页码:2051 / U100
页数:13
相关论文
共 50 条
  • [41] Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Neoplasms
    Diamond, Eli L.
    Durham, Benjamin
    Dogan, Ahmet
    Yabe, Mariko
    Petrova-Drus, Kseniya
    Rampal, Raajit K.
    Ulaner, Gary
    Lacouture, Mario
    Rotemberg, Veronica
    Covey, Anne
    Brody, Lynn
    Abdel-Wahab, Omar
    BLOOD, 2023, 142
  • [42] SINGLE-AGENT CARBOPLATINUM FOR ADVANCED SEMINOMA - A PHASE-II STUDY
    SCHMOLL, HJ
    HARSTRICK, A
    BOKEMEYER, C
    DIECKMANN, KP
    CLEMM, C
    BERDEL, WE
    SOUCHON, R
    SCHOBER, C
    WILKE, H
    POLIWODA, H
    CANCER, 1993, 72 (01) : 237 - 243
  • [43] Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors
    Rubin, EH
    Rothermel, J
    Tesfaye, F
    Chen, TL
    Hubert, M
    Ho, YY
    Hsu, CH
    Oza, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9120 - 9129
  • [44] Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis
    Duan, Weiwei
    Peng, Yuyao
    Jin, Wanlin
    Ouyang, Song
    Yang, Huan
    JOURNAL OF IMMUNOLOGY RESEARCH, 2021, 2021
  • [45] Current Status of Clinical Trials for Childhood Liver Tumors in Japan
    Ida, Kohmei
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S9 - S10
  • [46] Current Status of Clinical Trials and Good Clinical Practice in Japan
    Tominaga T.
    Drug information journal : DIJ / Drug Information Association, 1997, 31 (4): : 1071 - 1078
  • [47] Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: An overview
    Shepherd, FA
    ANTI-CANCER DRUGS, 1995, 6 : 19 - 25
  • [48] Experience with adjuvant single-agent carboplatin therapy for clinical stage I seminoma
    Morales-Barrera, R.
    Chilaca Rosas, M.
    Molina-Calzada, C.
    Arrieta, O. G.
    Alvarez-Avittia, M.
    de la Garza, J.
    Calderillo, G.
    Jimenez-Rios, M. A.
    Calvo-Aller, E.
    Aguilar-Ponce, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Phase I dose escalation and pharmacokinetic study of single-agent protein kinase C β inhibitor, LY317615.
    Herbst, RS
    Thornton, DE
    Sinha, V
    Flanagan, S
    Cassidy, C
    Teicher, B
    Carducci, MA
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3658S - 3659S